Schrodinger, Inc. cash flow statement
In fiscal 2025, Schrodinger, Inc.'s operations generated $13.9m of cash; it spent $1.4m on capital projects, leaving free cash flow of $12.5m.
Cash flow statement
| Fiscal year | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −26 | 17 | −71 | −120 | −137 | −157 | 14 | −127 |
| Depreciation and amortisation | 4 | 4 | 3 | 4 | 6 | 6 | 6 | 6 |
| Stock-based pay | 2 | 11 | 26 | 40 | 48 | 50 | 43 | 39 |
| Capital spending | 2 | 3 | 7 | 8 | 13 | 7 | 1 | 3 |
| Free cash flow | −28 | 14 | −78 | −128 | −150 | −165 | 12 | −130 |
| Free cash flow after stock pay | −30 | 4 | −104 | −167 | −198 | −215 | −31 | −169 |
| Shares issued | — | — | — | 0 | 0 | 9 | 0 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | −33 | −31 | 144 | −52 | −62 | −16 | −15 | −34 |
| Depreciation and amortisation | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 |
| Stock-based pay | 12 | 12 | 12 | 11 | 11 | 10 | 9 | 9 |
| Capital spending | 1 | 1 | 1 | 0 | 0 | 0 | 3 | 0 |
| Free cash flow | −35 | −32 | 143 | −53 | −62 | −16 | −17 | −34 |
| Free cash flow after stock pay | −47 | −44 | 132 | −63 | −73 | −26 | −26 | −43 |
| Shares issued | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
Compare with peers
- Mesa Laboratories Inc cash flow
- Maravai Lifesciences Holdings, Inc. cash flow
- Fulgent Genetics, Inc. cash flow
- Cytek Biosciences, Inc. cash flow
- Castle Biosciences Inc cash flow
Head to head: MLAB vs SDGRMRVI vs SDGRFLGT vs SDGRCSTL vs SDGR
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies